Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A recent study links simplified HIV treatment with a greater risk of inflammation.
Previous studies found Tivicay monotherapy was subpar, but this trial switched people to the drug who had started combo treatment early.
So argued researchers behind a study that switched people from triple-antiretroviral regimens to Tivicay monotherapy.
Initially, a recent study had shown promise that dolutegravir monotherapy was as effective as combination therapy.
In the HIV cure research effort, finding ways to reduce the hidden stores of the virus is key.
Among HIV-positive people, it is preferable to treat hepatitis B with a two-drug regimen rather than with monotherapy.
Merck’s investigatory non-nuke MK-1439 proved safe and well tolerated—and it displayed robust antiviral activity in a small early trial.
Not only was Kaletra (lopinavir plus ritonavir) monotherapy inferior to standard three-drug treatment in people with HIV, but rising HIV level...
People taking once-daily Norvir (ritonavir)-boosted Prezista (darunavir) monotherapy were able to maintain control over HIV for 96 week about...
Switching to Norvir-boosted Prezista monotherapy after achieving an undetectable viral load using combination ARV treatment worked well
Infants exposed to single-dose Viramune (nevirapine) monotherapy at the time of delivery—potentially resulting in rapid resistance to th...
Those on Kaletra therapy were as likely as people who stayed on a three-drug regimen to have treatment success
More than 10 years after combination HIV treatment was heralded as the one and only way to treat HIV, data continue to emerge suggesting that...
Ten years after combination HIV treatment was heralded as the one and only way to treat HIV, data are emerging to suggest that monotherapyR...
The art of cocktail chatter
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.